Merck & Co.’s Ebola vaccine and an antiviral drug from Gilead Sciences are set for wider use in eastern Democratic Republic of Congo to blunt the fastest-growing Ebola outbreak on record https://t.co/SeCRTlNnyi ...

Market Trends and M&A Opportunities - Mergers and acquisitions activity is surging due to the transition from the Biden administration's strict antitrust enforcement to the Trump administration's minimal antitrust enforcement [1] - Corporate acquirers are highly motivated and willing to pay premium prices for blockbuster deals, such as potential bids by AstraZeneca for Bristol Myers or Stripes for PayPal [2][3] - Investment strategy advises against purchasing potential target stocks, focusing instead on deal-enabling financial institutions like Goldman Sachs and Morgan Stanley due to their lucrative M&A advisory businesses [3][4] Sector Rotation and Healthcare Performance - Portfolio managers are shifting focus from technology stocks to innovative non-tech sectors, highlighting pharmaceutical leaders like Eli Lilly and Johnson & Johnson following their strong quarterly results [5][6] - Moderna has achieved a significant milestone by receiving FDA approval for its mRNA flu vaccine, contributing to an 83% surge in its stock price for the year [6][7] - Investment sectors recommended for the remainder of 2026 include travel stocks, semiconductor capital equipment makers, cybersecurity companies, M&A facilitators, and medical technology [8]

A Texas-based compounding pharmacy is recalling certain lots of a popular peptide called glutathione after they were found to be contaminated with bacterial toxins https://t.co/YNS9Yi1M3i ...

The FDA approved the first drug to treat a root cause of narcolepsy, which could help other sleep conditions as well. https://t.co/ySoECVg6ki ...

Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound and Foundayo will be available at a cost of $50 a month. https://t.co/bwTJnpoe2b ...